Abstract
This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C-->T (odds ratio, 0.254; P=.021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P<.001).
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adult
-
Alkynes
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / metabolism
-
Anti-HIV Agents / therapeutic use
-
Aryl Hydrocarbon Hydroxylases / genetics
-
Benzoxazines
-
Case-Control Studies
-
Chemical and Drug Induced Liver Injury*
-
Cyclopropanes
-
Cytochrome P-450 CYP2B6
-
Cytochrome P-450 CYP3A
-
Cytochrome P-450 Enzyme System / genetics*
-
Female
-
Genes, MDR*
-
Genetic Variation
-
Genotype
-
HIV Infections / drug therapy
-
HIV-1
-
Humans
-
Liver / drug effects
-
Liver Diseases / genetics
-
Liver Diseases / virology
-
Male
-
Nevirapine / adverse effects*
-
Nevirapine / metabolism
-
Nevirapine / therapeutic use
-
Oxazines / adverse effects*
-
Oxazines / metabolism
-
Oxazines / therapeutic use
-
Oxidoreductases, N-Demethylating / genetics
-
Reverse Transcriptase Inhibitors / adverse effects*
-
Reverse Transcriptase Inhibitors / metabolism
-
Reverse Transcriptase Inhibitors / therapeutic use
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
Cyclopropanes
-
Oxazines
-
Reverse Transcriptase Inhibitors
-
Cytochrome P-450 Enzyme System
-
Nevirapine
-
Aryl Hydrocarbon Hydroxylases
-
CYP2B6 protein, human
-
Cytochrome P-450 CYP2B6
-
Cytochrome P-450 CYP3A
-
CYP3A4 protein, human
-
Oxidoreductases, N-Demethylating
-
efavirenz